Jump to full article: The Wall Street Journal Interactive Edition, 2002-05-30 Author: GORDON FAIRCLOUGH / Staff Reporter of THE WALL STREET JOURNAL
Intro: Philip Morris Cos. agreed to sell its Miller Brewing unit to South African Breweries PLC of London in a $5.6 billion transaction that would give the tobacco and food giant a sizable stake in the world's second-biggest beer company. . .
Mr. Camilleri, in his first interview since taking the reins at the end of April, said Philip Morris intends to be aggressive about deal-making. Mr. Camilleri, who as the company's chief financial officer had been instrumental in the acquisition of Nabisco Holdings Corp., said, "We will continue to pursue large acquisitions, but we will be very disciplined about it."
Another top priority, he said, is rewarding shareholders by using the company's cash for dividends and to buy back stock. The Miller deal, which he personally helped orchestrate, would further those objectives. . .
Martin Feldman, a tobacco analyst at Merrill Lynch & Co., believes the SAB deal is a harbinger of things to come. He said he expects Mr. Camilleri's tenure to be marked by "the use of well-structured deals to accelerate earnings growth and increase returns to shareholders." . .
Mr. Camilleri said he is on the prowl for companies to acquire. "My own sense is, we'll stick to food and tobacco, because we still see considerable potential in both those industries," he said, adding that most deals in the near future would be smaller, incremental additions. . .
Another potential growth engine for the company and a way to gain market share, Mr. Camilleri said, is by selling a potentially less hazardous cigarette. Mr. Camilleri has designated Michael E. Szymanczyk, now chairman of the company's domestic-tobacco operations, to shepherd to market a new smoke under development that contains lower levels of a broad range of harmful chemicals than regular cigarettes.
Mr. Camilleri said that government regulation of such products could help get them to market. That is one of the reasons, he said, that Philip Morris is lobbying Congress to give the Food and Drug Administration jurisdiction over tobacco. Mr. Camilleri already has been to Washington to meet with members of Congress and explain the company's position. "Having a regulatory framework is very important to restore our credibility in the eyes of society," he said.
Jump to full article » |